AbbVie (NYSE:ABBV) Stock Price Up 3% – Still a Buy?

AbbVie Inc. (NYSE:ABBV) traded up 3% during mid-day trading on Thursday . The stock traded as high as $229.05 and last traded at $227.5660. 8,689,308 shares changed hands during mid-day trading, an increase of 14% from the average session volume of 7,633,555 shares. The stock had previously closed at $220.89.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY?2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin?based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later?stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real?world / post?marketing data — Completion of a Korean post?market study adds supportive real?world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug?price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near?term upside and may limit multiple expansion. Evercore ISI Cuts PT

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Evercore decreased their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. Citigroup lowered their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research report on Tuesday, January 20th. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 price target (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Finally, UBS Group cut their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $251.00.

AbbVie Price Performance

The stock’s fifty day simple moving average is $223.56 and its two-hundred day simple moving average is $220.64. The company has a market capitalization of $409.28 billion, a price-to-earnings ratio of 98.12, a PEG ratio of 0.79 and a beta of 0.35.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

Hedge Funds Weigh In On AbbVie

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABBV. Brighton Jones LLC boosted its holdings in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after acquiring an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares during the period. Harbor Asset Planning Inc. bought a new position in AbbVie during the 2nd quarter valued at $58,000. Nordea Investment Management AB increased its position in shares of AbbVie by 10.0% during the 2nd quarter. Nordea Investment Management AB now owns 4,489,477 shares of the company’s stock valued at $833,651,000 after purchasing an additional 409,190 shares during the period. Finally, Oxbow Advisors LLC raised its stake in shares of AbbVie by 227.5% in the 2nd quarter. Oxbow Advisors LLC now owns 22,987 shares of the company’s stock worth $4,267,000 after buying an additional 15,967 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.